InvestorsHub Logo
icon url

Work Harder

02/21/21 11:12 AM

#23207 RE: Work Harder #23206

Vaccinex shares vroom higher on mystery discovery deals

Feb. 19, 2021

By Michael Fitzhugh

News of Vaccinex Inc. signing two multitarget deals with undisclosed "prominent pharmaceutical companies" sent company shares (NASDAQ:VCNX) up 70% to $4.88 on Feb. 19, even as financial terms of the deal went undisclosed. The collaborations will focus on using the company's ActivMAb antibody discovery and novel viral display platform to develop candidates against complex antigens such as G protein-coupled receptors and ion channels, the company said.

https://www.bioworld.com/articles/503833-vaccinex-shares-vroom-higher-on-mystery-discovery-deals?v=preview

Collaboration Partner: Merck KGaA, Darmstadt, Germany
Clinical evaluation of the safety and effectiveness of VX15/2503 in combination with avelumab (anti-PD-L1) in the treatment of advanced non-Small Cell Lung Cancer (NSCLC).
ClinicalTrials.gov Identifier: NCT03268057

https://vaccinex.com/partners/

IO Biotech Completes Oversubscribed EUR 127 Million Series B Financing to Accelerate Clinical Programs in Oncology

https://www.iobiotech.com/index.php/news

T-win® technology baby

Hugo says major exposure coming

:}